La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that Deirdre Y. Gillespie, M.D., President and Chief Executive Officer, will present on Tuesday, September 18, at 11:45 a.m. Eastern Time during the A.G. Edwards Growth Conference. The conference will take place at The Palace Hotel in New York City.
Additionally, Dr. Gillespie will present during the 2007 UBS Global Life Sciences Conference on Monday, September 24, at 4:00 p.m. Eastern Time. The conference will take place at the Grand Hyatt in New York City. An audio webcast of each presentation will be available through the Company’s Web site: http://www.ljpc.com.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company’s leading product in development is Riquent®, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed potential small molecule drug candidates to treat various other autoimmune and inflammatory conditions. The Company's common stock is traded on The NASDAQ Global Market under the symbol LJPC. More information about the Company is available on its Web site: http://www.ljpc.com.
This press release and the presentations may contain forward-looking statements within the meaning of the federal securities laws. When used, the words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “result,” “should,” “will” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Forward-looking statements are subject to risks and uncertainties, both known and unknown and often beyond the Company’s control, and are not guarantees of future performance insofar as actual events or results may vary materially from those anticipated. Factors that may cause such a variance consist of, among others, those discussed from time to time in the Company’s filings with the Securities and Exchange Commission, including the risks described in “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2006, and specifically the Company’s ability to: demonstrate sufficiently Riquent’s efficacy and safety in clinical trials; manufacture Riquent on an adequate scale for clinical use; or develop further and commercialize Riquent successfully, either on its own or with a partner. The Company expressly disclaims any responsibility to update forward-looking statements.
La Jolla Pharmaceutical Company
Andrew Wiseman, Ph.D., Sr. Director of Investor Relations
858-646-6615
andrew.wiseman@ljpc.com
or
Media Contact:
Investor Relations Partners, Inc.
Shellie M. Roth, President, 973-535-8389
roth@irpartners.com